Ajanta Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Ajanta Pharma Ltd reported a 5.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 24.8%.
• Its expenses for the quarter were up by 9.1% QoQ and 23.6% YoY.
• The net profit decreased 2.6% QoQ and increased 18.4% YoY.
• The earnings per share (EPS) of Ajanta Pharma Ltd stood at 21.34 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ajanta Pharma Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company focuses on therapeutic segments such as cardiology, dermatology, ophthalmology, and pain management. Ajanta Pharma is known for its emphasis on research and development, continuously working towards introducing innovative products in the market. Although specific recent developments for the company are not mentioned in the data, Ajanta Pharma has historically been active in expanding its international presence and strengthening its product portfolio.

Revenue

In the fourth quarter of fiscal year 2026, Ajanta Pharma Ltd reported a total income of ₹1483.07 crores. This represents an increase of 5.9% over the previous quarter (Q3FY26), where the total income was ₹1399.81 crores, and a significant year-over-year growth of 24.8% compared to Q4FY25, where the total income was ₹1188.52 crores. This growth trajectory indicates an upward trend in revenue generation for the company during this period. The increase in total income could be attributed to various factors including, but not limited to, the introduction of new products, expansion into new markets, or increased market share in existing areas of operation.

Profitability

Ajanta Pharma Ltd's profitability metrics for Q4FY26 show a mixed performance. The company reported a profit before tax of ₹347.11 crores, which, although slightly lower than the previous quarter's ₹358.60 crores, shows a robust year-over-year increase of 28.8% from ₹269.41 crores in Q4FY25. The tax expense for the quarter was ₹80.41 crores, down from ₹84.83 crores in Q3FY26 but significantly higher than ₹44.15 crores in Q4FY25, reflecting an 82.1% increase year-over-year. As a result, the profit after tax for Q4FY26 stood at ₹266.70 crores, experiencing a minor decline of 2.6% QoQ from ₹273.77 crores in Q3FY26 but an 18.4% increase YoY from ₹225.26 crores in Q4FY25. The earnings per share also followed a similar pattern with a QoQ decrease of 2.6% but an 18.6% YoY increase.

Operating Metrics

The total expenses for Ajanta Pharma Ltd in Q4FY26 were reported at ₹1135.96 crores, marking an increase of 9.1% from the previous quarter's ₹1041.21 crores and a 23.6% increase from ₹919.11 crores in Q4FY25. This rise in expenses could be indicative of increased operational activities, investment in research and development, or expansion costs. Despite the increase in expenses, the company's earnings have shown growth, suggesting a strong operational performance. The performance metrics indicate that Ajanta Pharma Ltd is maintaining substantial operational throughput, reflected in the financial results for the quarter.